Check patentability & draft patents in minutes with Patsnap Eureka AI!

Application of miR-142-5p in preparation of medicine for treating chronic myelogenous leukemia

A technology for chronic myeloid cells and leukemia, which can be used in the field of biomedicine to solve problems such as adverse drug reactions

Inactive Publication Date: 2021-05-14
CHINA PHARM UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Tyrosine kinase inhibitors (TKIs) are currently the first-line drugs for the treatment of CML, which have greatly alleviated the condition of CML patients, but there are adverse drug reactions and BCR-ABL kinase-dependent (for example, BCR-ABL kinase domain point mutations and compound mutations, BCR-ABL gene overexpression) drug resistance and drug resistance independent of BCR-ABL kinase (for example, the existence of CML stem cells and compensatory survival pathways, etc.), therefore, the search for new CML Therapeutic targets are important

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of miR-142-5p in preparation of medicine for treating chronic myelogenous leukemia
  • Application of miR-142-5p in preparation of medicine for treating chronic myelogenous leukemia
  • Application of miR-142-5p in preparation of medicine for treating chronic myelogenous leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] 1. Materials and methods

[0032] 1.1 Cell lines and cell culture

[0033] HS-5, K562, and 293T cells were purchased from Jiangsu KGI Biotechnology Co., Ltd. K562 cells were cultured in RPMI-1640 culture medium (Jiangsu Kaiji Biotechnology Co., Ltd.) containing 10% fetal bovine serum (BI Company of the United States), and 293T cells were cultured in DMEM medium containing 10% fetal bovine serum (Jiangsu Kaiji Biotechnology Co., Ltd.). Biotechnology Co., Ltd.) in 5% CO 2 , in a 37°C humidified incubator.

[0034] 1.2 RT-qPCR detection of miR-142-5p and gene mRNA expression levels

[0035] 1.2.1 Extraction of total RNA from cell samples

[0036] Operate in an RNase-free environment, strictly in accordance with the instructions of the Trizol kit (Invitrogen, USA).

[0037] (1) Collect an appropriate amount of cells washed with PBS, add 1ml Trizol, pipette well, and incubate on ice

[0038] 5min. Completely dissolves nucleoprotein complexes.

[0039] (2) Add 0.2ml / tub...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicine, particularly to an effect of miR-142-5p in treatment of chronic myelogenous leukemia (CML). It is found in the invention that the expression of the miR-142-5p in the CML cells is reduced, and CML cell proliferation can be inhibited and cell apoptosis can be induced by recovering the expression of the miR-142-5p. Meanwhile, a target mRNA is found by carrying out transcriptome sequencing analysis on the K562 cell of the overexpressed miR-142-5p. The miR-142-5p can regulate the growth of the CML cells by inhibiting a PI3K / AKT signal channel. The invention discloses a molecular mechanism based on the interaction of miRNA and PIK3CD, so the miR-142-5p can be used for adjuvant therapy of CML.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and relates to the application of miR-142-5p in treating CML. Background technique [0002] Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by malignant transformation of hematopoietic stem cells, characterized by the translocation of the c-abl proto-oncogene on chromosome 9 to the BCR on chromosome 22 resulting in the Philadelphia of the BCR-ABL gene (philadelphia chromosome, Ph) Chromosome formation. P210 encoded by the BCR-ABL fusion gene bcr-abl The fusion protein has persistently activated tyrosine kinase activity, which can continuously phosphorylate and activate multiple downstream signaling pathways, such as Ras, phosphoinositide 3-kinase (PI3K) / protein kinase B (AKT), signal transducer and activator of transcription (STATs) and control apoptosis signals, etc., and then affect cell proliferation, differentiation and apoptosis, causing CML and about 30% of acute...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/7105A61P35/02
CPCA61K45/00A61K31/7105A61P35/02
Inventor 王淑珍刘琦
Owner CHINA PHARM UNIV
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com